GENE THERAPY. REDEFINED.
LIVE

Serial Number

98612779

Owner

Kriya Therapeutics, Inc.

Attorney

Monica Riva Talley

Filing Date

Jun 21, 2024

Add to watchlist:

No watchlists yet
View on USPTO

GENE THERAPY. REDEFINED. Trademark

Serial Number: 98612779

GENE THERAPY. REDEFINED. is a trademark filed by Kriya Therapeutics, Inc. on June 21, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Kriya Therapeutics, Inc. (24 trademarks)

Palo Alto, CA 94306

Entity Type: 03

Trademark Details

Filing Date

June 21, 2024

Registration Date

Not Registered

Published for Opposition

May 13, 2025

Goods & Services

Pharmaceutical preparations for gene therapy for the treatment of chronic diseases, cancer, or infectious diseases, namely, metabolic, endocrine, ophthalmic, oncological, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, hepatological, respiratory, viral, neurological, gastrointestinal, hormonal, dermatological, and immune-system-related diseases and disorders; pharmaceutical preparations for the treatment of chronic diseases, cancer, or infectious diseases, namely, metabolic, endocrine, ophthalmic, oncological, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, hepatological, respiratory, viral, neurological, gastrointestinal, hormonal, dermatological, and immune-system-related diseases and disorders

Testing, inspection, research, or development of pharmaceutical preparations for gene therapy; research and development in the pharmaceutical and biotechnology fields relating to the treatment of chronic diseases, cancer, or infectious diseases, namely, metabolic, endocrine, ophthalmic, oncological, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, hepatological, respiratory, viral, neurological, gastrointestinal, hormonal, dermatological, and immune system related diseases and disorders

Biomanufacturing for others, namely, manufacturing of pharmaceuticals using biological organisms in the manufacturing process; providing technical information in the field of pharmaceutical manufacturing

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 24, 2026 EXRA
SOU EXTENSION 2 GRANTED
Jun 23, 2026 EX2G
SOU EXTENSION 2 FILED
Jun 23, 2026 EXT2
SOU TEAS EXTENSION RECEIVED
Jun 23, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 20, 2025 EXRA
SOU EXTENSION 1 GRANTED
Dec 19, 2025 EX1G
SOU EXTENSION 1 FILED
Dec 19, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Dec 19, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 8, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 13, 2025 NPUB
PUBLISHED FOR OPPOSITION
May 13, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 7, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 10, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Apr 10, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Apr 10, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Apr 10, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Apr 10, 2025 CNEA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 16, 2025 GNRN
NON-FINAL ACTION E-MAILED
Jan 16, 2025 GNRT
NON-FINAL ACTION WRITTEN
Jan 16, 2025 CNRT
ASSIGNED TO EXAMINER
Jan 15, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 14, 2025 NWOS
NEW APPLICATION ENTERED
Jun 21, 2024 NWAP